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Use of Diuretics is not associated with
mortality in patients admitted to the
emergency department: results from
a cross-sectional study
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Thomas C. Sauter1, Valentin Fuhrmann4 and Aristomenis K. Exadaktylos1
Abstract
Background: Patients with diuretic therapy are at risk for drug-induced adverse reactions. It is unknown if presence
of diuretic therapy at hospital emergency room admission is associated with mortality.
Methods: In this cross sectional analysis, all emergency room patients 2010 and 2011 at the Inselspital Bern,
Switzerland were included. A multivariable logistic regression model was performed to assess the association
between pre-existing diuretic medication and 28 day mortality.
Results: Twenty-two thousand two hundred thirty-nine subjects were included in the analysis. A total of 8.5 %,
2.5 %, and 0.4 % of patients used one, two, or three or more diuretics. In univariate analysis spironolactone,
torasemide and chlortalidone use were associated with 28 day mortality (all p < 0.05). In a multivariate cox
regression model no association with mortality was detectable (p > 0.05). No difference existed between patients
with or without diuretic therapy (P > 0.05). Age and creatinine were independent risk factors for mortaliy
(both p < 0.05).
Conclusion: Use of diuretics is not associated with mortality in an unselected cohort of patients presenting in an
emergency room.
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Background
Diuretics are an established pharmacotherapy for dis-
eases such as hypertension, symptomatic heart failure or
the nephrotic syndrome. Adverse effects include electro-
lyte disorders and volume depletion [1]. In an ageing
population, the number of patients treated with diuretics
is increasing, and is paralleled by side effects [2, 3].
Studies investigating diuretic therapy-induced electro-
lyte disorders have mainly focused on the effects of thia-
zide diuretics. In a randomized controlled trial in
hypertensive patients, serum potassium levels were sig-
nificantly lower in patients receiving thiazide diuretics
[4]. However, only patients who did not receive potas-
sium supplements developed marked hypokalemia with
potassium levels below 3.0 mmol/L [4]. A more recent
study on hypertensive patients found an incidence of
30 % for hyponatremia in patients treated with thiazide
diuretics [5], which was not associated with an increased
risk of hospitalization or death.
Use of diuretic therapy is associated with acute kidney
injury or mortality in postsurgical patients [6–8]. While
the association of pre-existing diuretic therapy with elec-
trolyte imbalances at emergency room admission has
been described previously [9], the relationship with mor-
tality is not known in this group of patients. The present
retrospective analysis has therefore studied whether pre-
existing use of diuretics at hospital admission serves as
an indicator of poor clinical outcome in this population.
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Materials, methods and patients
All patients admitted to the ER of the Inselspital, Uni-
versity Hospital Bern, between 1 January 2009 and 31
December 2010 were included in this cross-sectional
analysis. During the study period 22239 patients were
enrolled into the study. In the case of multiple admis-
sions, only the first admission to the ER was considered
for the analysis. Patient data was anonymized for ana-
lysis and de-identified prior to analysis.
For these 22239 patients, data on age, sex, admission
type (medical or surgical), pre-existing diuretic medica-
tion, country of residence, hospital admission, length of
hospital stay, outcome and final diagnosis as classified
by the International Classification of Diseases, 10th revi-
sion (ICD-10) were collected.
Daily dose of the following diuretic medicines was cal-
culated: hydrochlorothiazide, chlorthalidone, butizide,
amiloride, spironolactone, eplerenone, furosemide, tora-
semide, indapamide, metolazone and acetazolamide.
A waiver for informed consent was provided for retro-
spective analysis of pseudononymized data. The study
protocol was approved by the Ethics Committee of the
Canton of Bern, Switzerland.
Statistical analysis
Data are presented as means ± standard deviation (SD),
medians or proportions, as appropriate. Between-group
comparisons of continuous variables were performed
using the Mann–Whitney U test.
Pearson’s Chi-Square Test was used for the identifica-
tion of associations with survival.
Multivariable logistic regression analysis was used to ex-
plore the association of the various predictors with the
presence of electrolyte disorders and with hospitalization.
Predefined covariates were added to the logistic regression
models. Cox regression was used to test associations of
the diuretics with the survival time adjusted for predefined
covariates.
A two-sided P value of <0.05 was considered statisti-
cally significant for all analyses. The statistical analysis
was performed using SPSS (SPSS for Windows V.17.0,
Chicago, IL, USA).
Results
Data from 22239 patients were included in the analysis.
The mean age at presentation was 52 years (SD 20) and
57 % were men. 76 % of patients were Swiss residents.
Of these 1939 (8.7 %) patients were admitted to the in-
tensive care unit. Reasons for admission were coded via
ICD classification and was available in 11898 patients. In
702 patients cancer, in 2884 patients intoxication, in 146
patients endocrinologic, in 1053 patients gastroenterolo-
gic, in 522 patients infectious, in 2831 patients cardio-
vascular, in 650 patients pulmonary, in 546 patients
musculo-sceletal, in 517 patients nephrologic/urologic,
in 1119 patients neurologic/psychiatric, in 928 patients
other (ear, eye, dermatologic) diseases were the reason
for admission.
Overall 587 (2.8 %) patients died within 28 days of
admission. Diuretic therapy is listed in Table 1. When
compared with patients without diuretic therapy, pa-
tients with diuretic therapy had a higher mortality
(Mann–Whitney-U, p < 0.001). However, there was no
significant difference in mortality between patients
with or without diuretic therapy in overall survival (p
= 0.088) and in mortality within 28 days in Kaplan
Meier analysis (Fig. 1).
In univariate analysis ethnicity, pre-existing diuretic
therapy, the amount of diuretics, and the medicines
chlorthalidon, spironolactone and torasemide were asso-
ciated with mortality (Table 2, all p < 0.05). With excep-
tion of furosemide dosage (p = 0.02) comparable results
were obtained when dosages of the respective diuretics
were tested for associations with survival (data not
shown). Admission to an intensive care unit (ICU) was
associated with mortality (p < 0.001).
In multivariate cox regression analysis use of diuretic
therapy was not associated with mortality (Table 3a).
This lack of an association was also observed for the dif-
ferent diuretic medicines (Table 3b). Age, ICU admission
and creatinine were the only factors associated with
mortality in this cohort (Table 3).
Discussion
Over a 2-year period, more than 20,000 patients seen in
our ER at a large tertiary care hospital for different rea-
son. A total of 11 % of subjects received concomitant di-
uretic treatment, and 3 % were taking more than one
diuretic agent. Diuretic therapy was not an independent
risk factor for mortality in these patients.
Table 1 Subject characteristics for diuretic therapy. Data shown
as absolute numbers and %
n (%)
Diuretic therapy 2401 (11.3)
Hydrochlorothiazid 936 (4.4)
Chlorthalidon 99 (0.5)
Butizid 11 (0.1)
Amilorid 93 (0.4)
Spironolacton 384 (1.8)
Furosemid 212 (1.0)
Torasemid 1143 (5.4)
Indapamid 52 (0.2)
Metolazon 115 (0.5)
Eplerenon 13 (0.1)
Diamox 20 (0.1)
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Diuretic therapy has been investigated in multiple
ways of either beneficially influencing heart failure, acute
kidney injury or by potentially increasing mortality by
increasing electrolyte disorders [10–12]. Our study dem-
onstrates associations of diuretic agents as torasemide,
spironolactone or chlortalidon with mortality in univari-
ate analysis. However, this finding was not robust in a
multivariate regression model. Therefore, one may raise
the suspicion that the risk associated with diuretic
therapy is rather related to the associated electrolyte dis-
orders than to the substances itself [9]. Interestingly, fur-
osemide itself was not associated with mortality.
However, its dosage was. Our results are in line with
those obtained in patients who underwent surgical pro-
cedures and consecutive acute kidney injury, where diur-
etic therapy was not associated with a higher mortality
[6]. We relate these findings to the fact that by increas-
ing renal insufficiency the dosage of furosemide in-
creases and therefore mortality raises. We could not
detect any difference between patients receiving diuretic
therapy and those without in overall mortality and mor-
tality with 28 days of hospital admission. This finding
further strengthens the hypothesis that mortality in crit-
ical ill patients is rather related to electrolyte disorders
or the higher morbidity of patients with existing diuretic
therapy.
Age, ICU admission and creatinine were dominant risk
factors in our study. These results are in line with other
studies [6–8]. In these studies post-surgical patients with
or without acute kidney injury were observed [6–8]. The
results suggested a potential influence of diuretic therapy
on mortality. However, these studies included markedly
older patients and patients who underwent major surgi-
cal procedures [6–8]. Further, in almost all of the prior
studies patients with acute kidney injury or the associ-
ation with this condition and diuretic use was investi-
gated [6–8]. We could not detect any association of the
respective substances with mortality.
Length of stay (28 days)
Fig. 1 Kaplan-Meier curve for mortality in patients with diuretics
(green line) versus patients without diuretics (blue line) mortality
within 28 days (p = 0.10)
Table 2 Associations of parameters with mortality in univariate
analysis, Chi-Square Test for binary and Mann–Whitney U test
for continuous variables (*p < 0.05)
p-value
Sex 0.074
Ethnicity 0.041*
Diuretic therapy <0.01*
Amount of diuretics <0.01*
Hydrochlorothiazid 0.834
Chlorthalidon 0.046*
Butizid 0.527
Amilorid 0.126
Spironolacton 0.009*
Furosemid 0.083
Torasemid <0.01*
Indapamid 0.188
Metolazon 0.645
Eplerenon 0.542
Diamox 0.450
Table 3 Multivariate cox regression analysis for the association
of different parameters with mortality, A) with diuretic therapy
as pooled parameter and B) with the respective substances
(*p < 0.05)
A
OR (CI) p-value
Age 0.97 (0.96;9.97) <0.01*
Black ethnicity 0.77 (0.19;3.15) 0.72
Creatinine 0.79 (0.74;0.85) <0.01*
ICU admission 0.11 (0.10;0.15) <0.01*
Diuretic therapy 1.11 (0.85;1.45) 0.43
B
OR (CI) p-value
Age 0.97 (0.96;9.97) <0.01*
Black ethnicity 0.77 (0.19;3.15) 0.72
Creatinine 0.79 (0.74;0.85) <0.01*
ICU admission 0.11 (0.10;0.15) <0.01*
Chlortalidon 0.52 (0.21;1.31) 0.16
Spironolactone 0.89 (0.52;1.53) 0.67
Torasemid 0.86 (0.62;1.20) 0.38
Furosemid 0.94 (0.48;1.83) 0.86
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One limitation of our study is that it was not practic-
able to obtain data on and evaluate all medications the
patients were taking because of the large number of pa-
tients included. Information on other substances that
may influence serum electrolytes apart from diuretics,
such as angiotensin-converting enzyme inhibitors, was
not available. Further, differences regarding admission
groups e.g. with specific cancer or coronary heart disease
might be present. However, our classification of admis-
sion diagnoses only covered wide topics as cardiovascu-
lar or infectious diseases.
One of the strengths of the study, however, was the
large number of patients included, and we therefore do
not expect that these limitations had a substantial effect
on our findings.
Conclusion
In daily use, diuretic therapy appears a common first line
therapy for many patients. Regarding electrolyte imbal-
ances they should always be subscribed with caution.
However, our results suggest that diuretic therapy is not
an independent risk factor for mortality in patients ad-
mitted to an emergency department.
Abbreviation
ICU: Intensive care unit; ER: Emergency room; SD: Standard deviation;
CI: Confidence interval; ICD: International classification of diseases.
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